Reply to Rappaport et al.: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19

Detalles Bibliográficos
Autores principales: Dutt, Tina, Simcox, David, Downey, Colin, McLenaghan, Daniella, King, Charlotte, Gautam, Manish, Lane, Steven, Burhan, Hassan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2020
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737584/
https://www.ncbi.nlm.nih.gov/pubmed/32931711
http://dx.doi.org/10.1164/rccm.202007-2913LE
_version_ 1783622967130849280
author Dutt, Tina
Simcox, David
Downey, Colin
McLenaghan, Daniella
King, Charlotte
Gautam, Manish
Lane, Steven
Burhan, Hassan
author_facet Dutt, Tina
Simcox, David
Downey, Colin
McLenaghan, Daniella
King, Charlotte
Gautam, Manish
Lane, Steven
Burhan, Hassan
author_sort Dutt, Tina
collection PubMed
description
format Online
Article
Text
id pubmed-7737584
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Thoracic Society
record_format MEDLINE/PubMed
spelling pubmed-77375842020-12-15 Reply to Rappaport et al.: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19 Dutt, Tina Simcox, David Downey, Colin McLenaghan, Daniella King, Charlotte Gautam, Manish Lane, Steven Burhan, Hassan Am J Respir Crit Care Med Correspondence American Thoracic Society 2020-12-15 2020-12-15 /pmc/articles/PMC7737584/ /pubmed/32931711 http://dx.doi.org/10.1164/rccm.202007-2913LE Text en Copyright © 2020 by the American Thoracic Society https://creativecommons.org/licenses/by-nc-nd/4.0/This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ). For commercial usage and reprints, please contact Diane Gern (dgern@thoracic.org).
spellingShingle Correspondence
Dutt, Tina
Simcox, David
Downey, Colin
McLenaghan, Daniella
King, Charlotte
Gautam, Manish
Lane, Steven
Burhan, Hassan
Reply to Rappaport et al.: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
title Reply to Rappaport et al.: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
title_full Reply to Rappaport et al.: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
title_fullStr Reply to Rappaport et al.: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
title_full_unstemmed Reply to Rappaport et al.: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
title_short Reply to Rappaport et al.: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
title_sort reply to rappaport et al.: anti-fxa activity with intermediate-dose thromboprophylaxis in covid-19
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737584/
https://www.ncbi.nlm.nih.gov/pubmed/32931711
http://dx.doi.org/10.1164/rccm.202007-2913LE
work_keys_str_mv AT dutttina replytorappaportetalantifxaactivitywithintermediatedosethromboprophylaxisincovid19
AT simcoxdavid replytorappaportetalantifxaactivitywithintermediatedosethromboprophylaxisincovid19
AT downeycolin replytorappaportetalantifxaactivitywithintermediatedosethromboprophylaxisincovid19
AT mclenaghandaniella replytorappaportetalantifxaactivitywithintermediatedosethromboprophylaxisincovid19
AT kingcharlotte replytorappaportetalantifxaactivitywithintermediatedosethromboprophylaxisincovid19
AT gautammanish replytorappaportetalantifxaactivitywithintermediatedosethromboprophylaxisincovid19
AT lanesteven replytorappaportetalantifxaactivitywithintermediatedosethromboprophylaxisincovid19
AT burhanhassan replytorappaportetalantifxaactivitywithintermediatedosethromboprophylaxisincovid19

Ejemplares similares